2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference

International Journal of Gynecological Cancer

Volumn 21, Issue 4, 2011, Pages 750-755

  Stuart, Gavin C E ^a   Kitchener, Henry ^b   Bacon, Monica ^a   DuBois, Andreas ^a   Friedlander, Michael ^a   Ledermann, Jonathan ^b   Marth, Christian ^a   Thigpen, Tate ^c   Trimble, Edward ^d  

^a CTG ^*  (Austria)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c Gynecologic Oncology Group (GOG)   (United States)

^d NCI US   (United States)

Author keywords

Gynecologic cancer intergroup; Ovarian cancer consensus conference

Indexed keywords

PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CYTOREDUCTIVE SURGERY; HEALTH CARE ORGANIZATION; HUMAN; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS;

CARCINOMA; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; CONSENSUS; FEMALE; GUIDELINES AS TOPIC; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; SOCIETIES, MEDICAL;

EID: 80051913984     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821b2568     Document Type: Conference Paper

References (9)

1. Allen DG, Baak J, Belpomme D, et al. Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol. 1993;4:S83-S88. (Pubitemid 24025502)
2. Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10:87-92.
3. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol. 2005; 16:viii7-viii12. (Pubitemid 41631227)
4. Quinn M, Avall-Lundqvist E, du Bois A, et al. History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004. Ann Oncol. 2005;16:viii5-viii6. (Pubitemid 41631226)
5. Katsumata N, Yasuda M, Takahashi F, et alfor the Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase III, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.
6. Armstrong D, Bunden B, Wenel L, et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med. 2006;354:34-43.
7. Vergote I, Tropé CG, Amant F, et alfor the European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group and the NCIC Clinical Trials Group-a Gynecologic Cancer Intergroup Collaboration. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
8. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol. 2010;28:LBA1 [abstract].
9. Perren T, Swart AM, Pfisterer J, et al. ICON7: phase III randomized Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol. 2010;:viii2-viii3. LBA4 [abstract].